Clinical trial
Somatuline Autogel: Acromegaly Self/Partner Injection Study
NCT00149188 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00149188 |
|---|---|
| Title | Somatuline Autogel: Acromegaly Self/Partner Injection Study |
| Official title | A Phase IV, Multicentre, Open Label, Controlled Study to Assess the Ability of Patients With Acromegaly, or Their Partners, to Administer Somatuline Autogel. |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acromegaly |
| Intervention type | Drug |
| Interventions | Lanreotide (Autogel formulation) |
| Enrollment | 30 |
| Start date | Feb 1, 2004 |
| Primary completion | Aug 24, 2005 |
| Completion | Aug 24, 2005 |
| First posted | Sep 8, 2005 |
| Last update posted | Aug 5, 2019 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: